

Patent Application
Attorney Docket No. PC25339A

I hereby certify that this correspondence is being sent by the United States Postal Service as first-class mail in an envelope addressed to: Mail Stop DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 30th day of June 2004.

By _____

A handwritten signature of Pamela C. Ancona.

(Signature of person mailing)

Pamela C. Ancona

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: John C. Kath *et al.*

APPLICATION SERIAL NO.: 10/734,039 : **Examiner:** Not Yet Assigned

FILING DATE: December 11, 2003 : **Group Art Unit:**

TITLE: COMPOUNDS FOR THE
TREATMENT OF ABNORMAL CELL
GROWTH

Mail Stop DD
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).


Patent Application
Attorney Docket No. PC25339A

Please charge all appropriate fees to cover this submission to Pfizer Deposit Account
No. 16-1445.

Respectfully submitted,

Date:

June 30, 2004



Pamela C. Ancona, Ph.D.
Attorney for Applicant(s)
Reg. No. 41,494

Pfizer, Inc
Patent Department, 5th Floor
150 East 42nd Street
New York, NY 10017-5755
(212) 733-6031

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>										ATTY. DOCKET NO. PC25339A	SERIAL NO. 10/734039	
APPLICANT John C. Kath et al.												
FILING DATE December 11, 2003										GROUP		

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER										DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
		5	5	2	1	1	8	4									
	(a)											May 28, 96	J. Zimmermann				
	(b)				4	5	0	7	1	4	6	Mar 26, 85	H. Tobler				
	(c)				5	8	6	3	9	2	4	Jan 26, 99	J. Berger				
	(d)	2	0	0	3	0	1	6	2	8	0	Aug 28, 03	J. Guo				
	(e)	2	0	0	3	0	1	8	1	4	7	Sep 25, 03	E. Pease				
	(f)	2	0	0	3	0	1	7	1	3	5	Sep 11, 03	G. Dahmann				
	(g)				6	2	9	7	2	5	8	Oct 2, 01	A. Wissner				
	(h)				5	7	5	3	6	6	3	May 19, 98	L. Flippin				
	(i)				4	9	8	3	6	0	8	Jan 8, 91	R. Effland				

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
	YES	NO													
(a)	0	3	0	3	2	9	9	7		Apr 24, 03	WO				
(b)		9	7	1	9	0	6	5		May 29, 97	WO				
(c)		0	1	6	0	8	1	6		Aug 23, 01	WO				
(d)		0	0	3	9	1	0	1		July 6, 00	WO				
(e)	0	2	0	9	6	8	8	7		Dec 5, 02	WO				
(f)	0	2	0	9	6	8	8	8		Dec 5, 02	WO				
(g)		0	2	1	6	3	4	8		Feb 28, 02	WO				
(h)		0	2	1	6	3	5	2		Feb 28, 02	WO				
(i)		0	2	1	2	2	2	7		Feb 14, 02	WO				
(j)		0	2	1	2	2	2	8		Feb 14, 02	WO				
(k)	0	3	0	9	5	4	4	8		Nov 20, 03	WO				
(l)		0	1	7	2	7	4	4		Oct 4, 01	WO				
(m)		9	9	4	1	2	5	3		Aug 19, 99	WO				
(n)	0	3	0	7	8	4	0	4		Sept 25, 03	WO				
(o)	0	3	0	3	0	9	0	9		April 12, 03	WO				
(p)		0	3	1	8	0	2	1		March 6, 03	WO				
(q)		0	3	6	3	7	9	4		Aug 7, 03	WO				
(r)	0	3	0	6	6	5	7	5		Aug 14, 03	WO				

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>						ATTY. DOCKET NO. PC25339A				SERIAL NO. 10/734039				
						APPLICANT John C. Kath et al.								
						FILING DATE December 11, 2003				GROUP				
(s)	0	2	0	2	0	5	0	1	Mar 14, 02	WO				
(t)	0	2	0	0	8	1	9	3	Jan 31, 02	WO				
(u)	0	1	0	6	8	1	8	6	Sep 20, 01	WO				
(v)	0	1	0	2	1	5	9	7	Mar 29, 01	WO				
(w)	0	0	0	1	8	7	4	0	Apr 6, 00	WO				
(x)		9	9	0	9	0	1	6	Feb 25, 99	WO				
(y)		9	8	3	7	0	7	9	Aug 27, 98	WO				
(z)		9	8	0	9	9	6	1	Mar 12, 98	WO				
(aa)		9	8	0	5	6	6	1	Feb 12, 98	WO				
(bb)		9	7	1	2	8	8	0	Apr 10, 97	WO				
(cc)		9	3	2	4	4	6	7	Dec 9, 93	WO				
(dd)		9	3	1	0	0	8	6	May 27, 93	WO				
(ee)			5	5	3	0	1	6	July 5, 97	EP				
(ff)			5	4	2	0	7	9	July 23, 97	EP				
(gg)			4	0	2	9	6	5	0	Mar 26, 92	DE			
OTHER DOCUMENTS (<i>Including Author, Title, Date, Pertinent Pages, Etc.</i>)														
			Search Report, 6/04/04, PCT/IB 03/05883											
			Knockaert, Marie et al: "Identifying in vivo targets of cyclin-dependent kinase inhibitors by affinity chromatography" <u>Biochemical Pharmacology</u> (2002), 64 (5-6), 819-825, XP002274117											
			Kath J C: "Patent Focus: Inhibitors of Tumour Cell Growth" <u>Expert Opinion on Therapeutic Patents</u> , Ashley Publications, GB, vo1.10, no.6, 2000, pages 803-818, XP000919385 Issn: 1354-3776											
			Stover D R et al: "Recent Advances in Protein Kinase Inhibition: Current Molecular Scaffolds Used for Inhibitor Synthesis" <u>Current Opinion in Drug Discovery and Development, Current Drugs</u> , London, GB, vol.2, no.4, 1999, pages 274-285, XP000926237 Issn: 1367-6733											
			Bramson, H. Neal et al: "Oxindole-Based Inhibitors of Cyclin-Dependent Kinase 2 (CDK2): Design, Synthesis, Enzymatic Activities, and X-ray Crystallographic Analysis" <u>Journal of Medicinal Chemistry</u> (2001), 44(25), 4339-4358, XP002274118											
EXAMINER						DATE CONSIDERED								
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE